Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Welcome and Introduction to Vi3C

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Peter Clark, MA, MD, FRCP: A Payer Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement

Jul

19

Today In Oncology

EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma

Study Finds Rising Breast Cancer Incidence Across Asian American, Native Hawaiian, and Pacific Islander Groups

Meta-Analysis Highlights Cardiovascular Safety Advantage of Second-Generation BTK Inhibitors

ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases

Tumor Microenvironment Ecotypes May Explain Differences in Multiple Myeloma Outcomes

Advertisement

© 2026 HSP News Service, L.L.C.